Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22965953 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Condition: Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Interventions: Drug: APR-246;   Drug: Carboplatin;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Indicates status has not been verified in more than two years